Literature DB >> 31896156

Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes.

Pedro Iglesias1, Karina Arcano2, Vanessa Triviño3, Fernando Guerrero-Pérez4, Víctor Rodríguez Berrocal5, Carlos Vior5, Fernando Cordido3, Carles Villabona4, Juan J Díez1.   

Abstract

BACKGROUND: Giant pituitary adenoma (≥4 cm) is a rare tumor whose clinical features and prognosis are not well known. AIM: To evaluate the clinical characteristics and therapeutic outcomes of giant non-functioning PA (gNFPA). PATIENTS AND METHODS: A retrospective multicenter study of gNFPA patients diagnosed in a 12-year period was performed. In each patient, clinical data and therapeutic outcomes were registered.
RESULTS: Forty patients (24 men, age 54.2 ± 16.2 years) were studied. The maximum tumor diameter [median (interquartile range)] was 4.6 cm (4.1-5.1). Women had larger tumors [4.8 cm (4.2-5.4) vs. 4.5 cm (4.0-4.9); p=0.048]. Hypopituitarism [partial (n=22, 55%) or complete (n=9, 22.5%)] at diagnosis was present in 77.5% of the patients. Visual field defects were found in 90.9%. The most used surgical technique was endoscopic endonasal transsphenoidal (EET) surgery (n=31, 77.5%). Radiotherapy was used in 11 (27.5%) patients (median dose 50.4 Gy, range 50-54). Thirty-seven patients were followed for 36 months (10-67 months). Although more than half of these patients showed tumor persistence (n=25, 67.6%), tumor size was significantly reduced [0.8 cm (0-2.5); p<0.001]. At last visit, 12 patients (32.4%) showed absence of tumor on MRI. Hypopituitarism rate was similar (75.0%), although with significant changes (p<0.001) in the distribution of the type of hypopituitarism. The absence of tumor at the last visit was positively associated with positive immunohistochemical staining for FSH (p=0.01) and LH (p=0.006) and negatively with female sex (p=0.011), cavernous sinus invasion (p=0.005) and the presence of Knosp grade 4 (p=0.013).
CONCLUSION: gNFPAs are more frequent in men but tumors are larger in women. Surgical treatment is followed by a complete tumor resection rate of approximately 30%. Positive immunostaining for gonadotropins is associated with tumor absence at last revision, while female sex and invasion of the cavernous sinuses with tumor persistence. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Year:  2020        PMID: 31896156     DOI: 10.1055/a-1017-3288

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  4 in total

1.  Prediction of the Recurrence of Non-Functioning Pituitary Adenomas Using Preoperative Supra-Intra Sellar Volume and Tumor-Carotid Distance.

Authors:  Wenli Chen; Mengqi Wang; Chengbin Duan; Shun Yao; Haosen Jiao; Zongming Wang; Bin Hu; Zhigang Mao; Yonghong Zhu; Haijun Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-30       Impact factor: 5.555

Review 2.  Hypogonadism in Male Patients with Pituitary Adenoma and Its Related Mechanism: A Review of Literature.

Authors:  Zisheng Yan; Ting Lei
Journal:  Brain Sci       Date:  2022-06-17

3.  Relationship with the diaphragm to predict the surgical outcome in large and giant pituitary adenomas.

Authors:  Ethan Harel; Giulia Cossu; Roy Thomas Daniel; Mahmoud Messerer
Journal:  Front Surg       Date:  2022-09-01

4.  Surgical management of giant pituitary neuroendocrine tumors: Meta-analysis and consensus statement on behalf of the EANS skull base section.

Authors:  Giulia Cossu; Emmanuel Jouanneau; Luigi M Cavallo; Sebastien Froelich; Daniele Starnoni; Lorenzo Giammattei; Ethan Harel; Diego Mazzatenta; Micheal Bruneau; Torstein R Meling; Moncef Berhouma; Ari G Chacko; Jan F Cornelius; Dimitrios Paraskevopoulos; Henry W S Schroeder; Idoya Zazpe; Romain Manet; Paul A Gardner; Henry Dufour; Paolo Cappabianca; Roy T Daniel; Mahmoud Messerer
Journal:  Brain Spine       Date:  2022-03-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.